久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

先聲藥業Simcere 
先聲藥業成立于1995年3月28日，至今，15歲的先聲已發展成為集生產、研發、銷售為一體，擁有 7家通過GMP認證的現代化藥品生產企業，2家全國性的藥品營銷企業、1家藥物研究院，擁有員工近 4000 人的新型藥業集團。

　　2005年，聯想控股公司下屬的弘毅投資出資2.1億元，持有先聲藥業31%的股份。2007年4月20日，先聲藥業成功登陸紐約證券交易所，募集資金2.61億美元，股票代碼SCR，成為中國內地第1家在紐交所上市的化學生物藥公司。

　　2009年，先聲藥業實現銷售收入18.50 億元，上繳國家稅收3. 41億元，實現凈利潤 1.20億元 。

　　目前，先聲藥業擁有45種以上藥品的強大產品組合，重點覆蓋腫瘤、心腦血管、感染等疾病治療領域。我們擁有“再林”，具有市場領先地位的阿莫西林品牌，享受單獨定價政策的“中國馳名商標”；“必存”，首入中國市場的抗腦卒中藥物，第一個作用機理明確的新型自由基清除劑；“恩度”，重組人血管內皮抑制素抗癌創新藥，擁有中國和美國的專利，并獲得第十屆中國專利金獎以及2008年度國家技術發明獎二等獎；以及其他3個年銷售額在7000萬以上或過億的品牌藥：英太青、必奇、安奇；其中，英太青是又一個 “中國馳名商標”，2009年成為NBA中國推廣合作伙伴。我們于2008年在國內首家上市的安信注射用比阿培南，為國內中、重度感染患者提供了新的治療選擇。2009年抗高血壓藥物欣他上市，先聲大步邁進心血管治療領域。同年，先聲藥業先后與上海賽金、江蘇延申兩家生物制藥企業展開股權合作，進一步進軍抗體和疫苗領域。先聲更多具備強大市場競爭力的品牌產品正在醞釀中。

　　先聲藥業在中國擁有廣泛的分銷網絡和專業化的營銷團隊，近 2000 名銷售人員和 近100家戰略合作伙伴，其中80%擁有醫學學位。在中國，先聲擁有超過1500家的經銷商。我們的產品營銷到超過4000家的中國醫院以及70000家藥店。每年，由先聲藥業主辦、承辦、協辦的各類學術會議上千場，制作的學術資料、論文匯編上百本，數以萬計的醫生因此更好的學習、交流、提高。

　　先聲藥業于2004年成立先聲藥物研究院，有數個技術平臺，可進行化學藥品和生物藥品的研究。目前已經申請或獲得中國發明專利共89件，成功開發上市首家、獨家品種10個。“一類新藥再暢片劑”項目獲得國家科技進步二等獎。2003年，經國家人事部批準，建立企業博士后科研工作站，先后有11位博士后進站。2006年1月，先聲藥業和清華大學建立“創新藥物聯合實驗室”，同時和南京大學、中國藥科大學、中國科學院上海藥物研究所、中國科學院上海有機化學研究所、美國愛德程實驗室、美國生物制藥企業Epitomics公司、OSI等單位 正在就新藥研發開展合作。2006年底，先聲藥物研究院面積超過5000平方米的現代化研發中心正式啟用，2008年底，上海國際醫學園研發基地開工建設。先聲藥業在南京、北京和上海的研發實驗室布局已初見雛形。 2009年10月，擁有更大規模、更先進設施，總投資近3個億的先聲藥物研究院二期工程正式破土動工。

　　先聲藥業的新藥研發以市場為導向，并聚焦于具有廣闊市場潛力的創新藥或中國市場上首先研制的品牌非專利藥。我們將研發努力集中于具有高發病率或高死亡率且具有更有效藥物需求的疾病治療領域，如癌癥、腦卒中、骨質疏松癥和感染性疾病。近年來，先聲藥業推出了中人氟安、捷佰舒、安信等一系列首入市場的品牌非專利藥或創新藥物，填補多項國內空白。目前，先聲藥業有10余個在研項目正處于不同的研究開發階段。

　　未來，先聲藥業的企業目標是成為中國創新藥物開發的領先者，在重大挑戰領域創造革命性藥物。我們正凝聚更多力量，為患者尋求和提供更有效藥物，讓員工為此而自豪，從而贏得客戶和社會的尊重。



When we founded Simcere on 28 March 1995, our vision was to establish a company that would in turn help create a healthier China. Since our founding, we have swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in the rapidly growing China pharmaceutical market. We now have six certified Good Manufacturing Practices ("GMP") manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and over 3,000 employees.
 

In recent years, we have continued to refine our strategy to focus on the development of first-to-market generic and innovative pharmaceuticals. We have introduced a first-to-market generic stroke management medication under the brand name Bicun, and an innovative anti-cancer medication under the brand name Endu. We currently manufacture and sell 39 principal pharmaceutical products and are the exclusive distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under our brand. In addition, we have obtained approvals from the SFDA to manufacture and sell over 210 other products. In our research and development efforts, we concentrate on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy. As of 31 March 2008, we had 12 product candidates in various stages of development, including treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, and nausea and vomiting associated with chemotherapy.

Our innovative anti-cancer medication Endu was granted an invention patent in China and was the first recombinant human endostatin injection approved for sale in China. Recombinant human endostatin is an engineered protein that inhibits the growth of blood vessels to a tumor, thereby starving and preventing the growth of cancer cells. Our generic anti-stroke medication Bicun was the first edaravone injection, a type of neuroprotective pharmaceutical compound, approved for sale in China. Our generic amoxicillin granule antibiotic, marketed under the brand name Zailin, was recognized as a "China Well-Known Trademark" in 2004 and our anti-inflammatory pain relievers for the treatment of rheumatoid arthritis and osteoarthritis, marketed under the brand name Yingtaiqing, was recognized as a "China Well-Known Trademark" in 2008. Both enjoy premium pricing as a result.

In September 2006, we acquired 80% of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd. for RMB 200 million, and launched our new patented anti-cancer drug, Endu (also known as "Endostar"). This was the first recombinant human endostatin successfully commercialized in the world and was one of the biggest Chinese pharmaceutical acquisitions targeting a single pharmaceutical product's intellectual property. The successful commercialization of Endu came about through the hard work and combined efforts of our R&D team, led by Dr. Yongzhang Luo, our independent clinical research team, headed by Dr. Yan Sun, and our professional sales and marketing team. Clinical research was conducted in 24 hospitals in China and an independent specialists committee audited the clinical research statistics and data. The results of our Phase III clinical studies on 493 Non-Small-Cell Lung Cancer ("NSCLC") patients showed that the Endu-plus-chemotherapy approach provides an effective alternative for treating NSCLC.

Going forward, we want to become a leading Chinese pharmaceutical company by providing innovative medicines that will reshape the future of the pharmaceutical industry in China. About 5000m2 research and development center in Nanjing provides us with a solid platform to support research activities that include synthetic research, drug analysis and pharmacological and cytological research. Our post-doctorate research workstation is benefiting from the efforts of 10 post-doctoral researchers and was certified by the State Ministry of Human Resources. To supplement our in-house research and development capabilities, we plan to increase our collaboration with domestic and international pharmaceutical and biotechnology companies and institutions along the lines of our Joint Laboratory for Drug Discovery together with Tsinghua University, which engages in the research and development of innovative pharmaceuticals. Simcere's commitment to research and development helps to ensure a robust pipeline of product candidates in various stages of development. With our deep knowledge about the Chinese pharmaceutical market, and increasing cooperation with domestic and international institutions, we are well positioned to provide quality products and services that will exceed our customers' expectations and help us meet the challenges of the new century.

Our employees are valuable business partners and internal customers, who share our beliefs and business vision. Simcere believes in helping every employee reach his/her maximum potential; we are devoted to investing our resources to ensure their success. A hunger for excellence is in the blood of every Simcere employee, and we all strive to create value for the company in a way which is consistent with our concerns for society at large.